| 2019 |
| 03/08 | 518 | 518 | 508 | 510 | -1.35% | 25,800 | 28億8445万 | +0.79% |
| 03/07 | 519 | 522 | 511 | 517 | -0.39% | 23,000 | 29億2404万 | +2.38% |
| 03/06 | 529 | 529 | 519 | 519 | -1.52% | 25,200 | 29億3536万 | +2.98% |
| 03/05 | 517 | 528 | 516 | 527 | 0% | 27,100 | 29億8060万 | +4.77% |
| 03/04 | 530 | 530 | 512 | 527 | 0% | 31,000 | 29億8060万 | +4.98% |
| 03/01 | 551 | 551 | 527 | 527 | -6.06% | 60,600 | 29億8060万 | +5.19% |
| 02/28 | 11:30 AACR年次総会におけるCBP501臨床試験データ発表について |
| 02/28 | 540 | 596 | 540 | 561 | +5.45% | 199,700 | 31億7290万 | +12.2% |
| 02/27 | 520 | 538 | 520 | 532 | +2.9% | 44,800 | 30億888万 | +7.04% |
| 02/26 | 535 | 535 | 517 | 517 | -3.36% | 24,900 | 29億2404万 | +4.23% |
| 02/25 | 536 | 536 | 513 | 535 | +1.33% | 22,800 | 30億2585万 | +7.86% |
| 02/22 | 532 | 538 | 520 | 528 | -0.94% | 38,300 | 29億8626万 | +6.67% |
| 02/21 | 524 | 536 | 517 | 533 | +3.7% | 46,000 | 30億1454万 | +7.68% |
| 02/20 | 501 | 519 | 500 | 514 | +1.58% | 13,900 | 29億708万 | +3.63% |
| 02/19 | 481 | 514 | 481 | 506 | +3.48% | 20,100 | 28億6183万 | +1.81% |
| 02/18 | 482 | 493 | 478 | 489 | +1.88% | 21,400 | 27億6568万 | -1.81% |
| 02/15 | 490 | 492 | 475 | 480 | +0.84% | 12,900 | 27億1478万 | -4.19% |
| 02/14 | 486 | 488 | 465 | 476 | -1.86% | 26,100 | 26億9216万 | -4.99% |
| 02/13 | 474 | 486 | 474 | 485 | +2.54% | 18,000 | 27億4306万 | -3.19% |
| 02/12 | 15:00 2019年6月期第2四半期決算短信〔日本基準〕(非連結) |
| 02/12 | 475 | 482 | 469 | 473 | -0.84% | 11,800 | 26億7519万 | -5.4% |
| 02/08 | 473 | 480 | 467 | 477 | -2.25% | 19,700 | 26億9781万 | -4.22% |
| 02/07 | 495 | 500 | 483 | 488 | -0.61% | 18,600 | 27億6003万 | -1.61% |
| 02/06 | 486 | 491 | 484 | 491 | +1.45% | 8,100 | 27億7699万 | -0.41% |
| 02/05 | 486 | 494 | 481 | 484 | +0.41% | 11,900 | 27億3740万 | -1.02% |
| 02/04 | 479 | 492 | 468 | 482 | +2.34% | 17,100 | 27億2609万 | -0.41% |
| 02/01 | 485 | 490 | 468 | 471 | -2.48% | 25,900 | 26億6388万 | -2.28% |
| 01/31 | 488 | 493 | 483 | 483 | -0.82% | 8,700 | 27億3175万 | +0.42% |
| 01/30 | 497 | 505 | 474 | 487 | -3.37% | 48,100 | 27億5437万 | +1.25% |
| 01/29 | 493 | 540 | 492 | 504 | +2.44% | 60,700 | 28億5052万 | +4.78% |
| 01/28 | 15:00 AACR年次総会における当社基礎研究成果のポスター発表について |
| 01/28 | 510 | 510 | 491 | 492 | -3.91% | 8,900 | 27億8265万 | +2.07% |
| 01/25 | 503 | 526 | 490 | 512 | +2.61% | 40,300 | 28億9576万 | +5.57% |
| 01/24 | 493 | 499 | 471 | 499 | +0.81% | 29,600 | 28億2224万 | +2.46% |
| 01/23 | 493 | 499 | 490 | 495 | -0.8% | 10,600 | 27億9962万 | +1.43% |
| 01/22 | 508 | 515 | 491 | 499 | -1.38% | 15,300 | 28億2224万 | +1.63% |
| 01/21 | 15:00 第三者割当による第2回無担保転換社債型新株予約権付社債の転換価額及び第14回新株予約権の行使価額の修正決定に関するお知らせ |
| 01/21 | 514 | 529 | 502 | 506 | -3.07% | 38,700 | 28億6183万 | +2.85% |
| 01/18 | 536 | 542 | 520 | 522 | -2.97% | 36,800 | 29億5232万 | +5.67% |
| 01/17 | 538 | 549 | 535 | 538 | -1.28% | 23,300 | 30億4282万 | +8.69% |
| 01/16 | 549 | 552 | 533 | 545 | +0.93% | 36,300 | 30億8241万 | +9.88% |
| 01/15 | 558 | 576 | 536 | 540 | -0.18% | 121,800 | 30億5413万 | +8.65% |
| 01/11 | 15:00 東京大学との共同研究契約拡大延長のお知らせ |
| 01/11 | 515 | 543 | 496 | 541 | -0.73% | 160,200 | 30億5978万 | +8.42% |
| 01/10 | 11:30 CBP501フェーズ1b試験拡大相FPI(最初の被験者への投与開始)のお知らせ |
| 01/10 | 480 | 561 | 471 | 545 | +13.31% | 366,800 | 30億8241万 | +9% |
| 01/09 | 483 | 484 | 466 | 481 | -0.62% | 24,500 | 27億2043万 | -4.18% |
| 01/08 | 476 | 490 | 468 | 484 | +5.22% | 37,400 | 27億3740万 | -4.35% |
| 01/07 | 440 | 471 | 433 | 460 | +6.48% | 37,700 | 26億166万 | -9.8% |
| 01/04 | 423 | 442 | 401 | 432 | +2.13% | 48,400 | 24億4330万 | -16.12% |
| 2018 |
| 12/28 | 402 | 426 | 402 | 423 | +1.2% | 51,100 | 23億9240万 | -18.97% |
| 12/27 | 396 | 419 | 396 | 418 | +8.85% | 30,800 | 23億6412万 | -20.98% |
| 12/26 | 382 | 399 | 377 | 384 | +4.07% | 81,200 | 21億7182万 | -28.36% |
| 12/25 | 374 | 380 | 366 | 369 | -11.51% | 121,600 | 20億8699万 | -32.17% |
| 12/21 | 423 | 436 | 402 | 417 | -6.71% | 92,500 | 23億5846万 | -24.73% |
| 12/20 | 473 | 477 | 432 | 447 | -8.59% | 81,300 | 25億2814万 | -20.32% |
| 12/19 | 505 | 510 | 481 | 489 | +0.82% | 47,800 | 27億6568万 | -13.6% |
| 12/18 | 15:30 CBP501臨床試験(フェーズ1b試験)拡大相被験者募集開始のお知らせ |
| 12/18 | 15:30 第2四半期及び通期業績予想の修正に関するお知らせ |
| 12/18 | 517 | 527 | 481 | 485 | -8.66% | 61,500 | 27億4306万 | -14.91% |
| 12/17 | 557 | 558 | 526 | 531 | -5.18% | 35,200 | 30億322万 | -7.65% |
| 12/14 | 558 | 570 | 546 | 560 | +0.36% | 34,800 | 31億6724万 | -3.11% |
| 12/13 | 549 | 558 | 545 | 558 | +3.33% | 60,700 | 31億5593万 | -3.96% |
| 12/12 | 544 | 548 | 536 | 540 | -1.82% | 28,500 | 30億5413万 | -7.22% |
| 12/11 | 530 | 550 | 527 | 550 | +3.38% | 22,900 | 31億1069万 | -5.82% |
| 12/10 | 552 | 552 | 525 | 532 | -3.8% | 29,500 | 30億888万 | -9.22% |
| 12/07 | 556 | 560 | 551 | 553 | -0.54% | 17,600 | 31億2765万 | -5.95% |
| 12/06 | 565 | 567 | 554 | 556 | -2.28% | 30,400 | 31億4462万 | -5.6% |
| 12/05 | 567 | 573 | 562 | 569 | -0.7% | 29,700 | 32億1815万 | -3.72% |
| 12/04 | 576 | 582 | 570 | 573 | -0.87% | 46,300 | 32億4077万 | -3.05% |
| 12/03 | 582 | 582 | 576 | 578 | +0.35% | 10,400 | 32億6905万 | -2.2% |
| 11/30 | 578 | 581 | 571 | 576 | -0.17% | 26,300 | 32億5774万 | -2.54% |
| 11/29 | 590 | 595 | 577 | 577 | -2.2% | 35,100 | 32億6339万 | -2.37% |
| 11/28 | 584 | 590 | 580 | 590 | +1.72% | 9,500 | 33億3692万 | -0.51% |
| 11/27 | 587 | 590 | 577 | 580 | -1.02% | 26,100 | 32億8036万 | -2.52% |
| 11/26 | 598 | 602 | 586 | 586 | -2.01% | 17,000 | 33億1429万 | -1.84% |
| 11/22 | 601 | 601 | 586 | 598 | -0.5% | 14,400 | 33億8216万 | -0.17% |
| 11/21 | 599 | 602 | 586 | 601 | -0.5% | 15,900 | 33億6908万 | 0% |
| 11/20 | 580 | 607 | 577 | 604 | +2.9% | 36,000 | 33億8590万 | +0.17% |
| 11/19 | 580 | 592 | 572 | 587 | -2.98% | 76,000 | 32億9060万 | -2.98% |
| 11/16 | 635 | 635 | 603 | 605 | +2.89% | 76,800 | 33億9150万 | -0.17% |
| 11/15 | 15:00 CBP501フェーズ1b試験用量漸増相中間とりまとめのお知らせ |
| 11/15 | 576 | 590 | 576 | 588 | +0.51% | 12,700 | 32億9621万 | -3.29% |
| 11/14 | 593 | 597 | 577 | 585 | -1.52% | 34,800 | 32億7939万 | -3.94% |
| 11/13 | 15:00 2019年6月期第1四半期決算短信〔日本基準〕(非連結) |
| 11/13 | 588 | 601 | 587 | 594 | -2.3% | 22,900 | 33億2984万 | -2.94% |
| 11/12 | 603 | 626 | 600 | 608 | -0.82% | 16,300 | 34億832万 | -0.82% |
| 11/09 | 611 | 627 | 605 | 613 | -0.81% | 28,800 | 34億3635万 | -0.33% |
| 11/08 | 603 | 629 | 601 | 618 | +4.22% | 26,000 | 34億6438万 | +0.16% |
| 11/07 | 585 | 639 | 585 | 593 | +0.68% | 88,400 | 33億2423万 | -4.2% |
| 11/06 | 592 | 594 | 583 | 589 | -0.34% | 9,600 | 33億181万 | -5.46% |
| 11/05 | 600 | 607 | 584 | 591 | -1.17% | 17,500 | 33億1302万 | -5.59% |
| 11/02 | 586 | 603 | 568 | 598 | +3.1% | 51,500 | 33億5226万 | -4.78% |
| 11/01 | 603 | 603 | 576 | 580 | -2.19% | 18,300 | 32億5136万 | -7.94% |
| 10/31 | 577 | 603 | 577 | 593 | +3.49% | 30,400 | 33億2423万 | -6.17% |
| 10/30 | 559 | 580 | 555 | 573 | +1.78% | 18,100 | 32億1212万 | -9.48% |
| 10/29 | 588 | 598 | 562 | 563 | -4.58% | 43,600 | 31億5606万 | -11.34% |
| 10/26 | 593 | 603 | 583 | 590 | +1.2% | 39,300 | 33億742万 | -7.52% |
| 10/25 | 611 | 613 | 583 | 583 | -5.2% | 50,300 | 32億6818万 | -8.76% |
| 10/24 | 629 | 636 | 615 | 615 | -2.38% | 16,600 | 34億4756万 | -3.91% |
| 10/23 | 634 | 647 | 615 | 630 | -0.63% | 33,800 | 35億3165万 | -1.56% |
| 10/23 | 9:00 CBS9106(SL-801)に関するESMO2018での発表について(続報) |
| 10/22 | 647 | 647 | 633 | 634 | -2.46% | 16,300 | 35億1603万 | -0.94% |
| 10/19 | 646 | 650 | 639 | 650 | -0.31% | 13,900 | 36億477万 | +1.72% |
| 10/18 | 648 | 659 | 642 | 652 | +1.4% | 34,600 | 36億1586万 | +2.35% |
| 10/17 | 650 | 650 | 640 | 643 | +0.16% | 15,300 | 35億6594万 | +1.1% |
| 10/16 | 9:30 CBS9106(SL-801)に関するESMO2018での発表について |
| 10/16 | 638 | 662 | 631 | 642 | +1.74% | 42,300 | 35億6040万 | +1.1% |
| 10/15 | 645 | 645 | 627 | 631 | -2.02% | 16,500 | 34億9939万 | -0.63% |
| 10/12 | 624 | 648 | 616 | 644 | +4.89% | 25,400 | 35億7149万 | +1.42% |
| 10/11 | 15:50 CBP501フェーズ1b試験拡大相の対象癌腫選定のお知らせ |
| 10/11 | 616 | 626 | 611 | 614 | -5.25% | 65,000 | 34億512万 | -3.46% |
| 10/10 | 632 | 650 | 630 | 648 | +2.69% | 33,500 | 35億9367万 | +1.73% |
